Fly News Breaks for March 2, 2015
HZNP
Mar 2, 2015 | 07:45 EDT
Brean Capital raised its price target on Horizon Pharma to $27 from $18 following its Q4 report, citing product demand, guidance, and operational leverage with the additional upside potential of M&A activity. Brean Capital reiterated its Buy rating on Horizon Pharma shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP